Back to Newsroom

Cempra’s Solithromycin Demonstrates Safety and Tolerability in Patients With Chronic Liver Disease

CHAPEL HILL, N.C., Sept. 5, 2013 — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that solithromycin demonstrated safety and tolerability in patients with mild to severe chronic liver disease. The pharmacokinetic analyses also showed that no dosage adjustments to compensate for decreased liver function were necessary in this patient population.